natgillin/translations-raw huggingface dataset:
The medicine 
dan.
The full EPAR for Leflunomide Teva can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Leflunomide Teva je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Two medicines are bioequivalent when they produce the same levels of the active substance in the body. 
Dve zdravili sta biološko enakovredni, ko dosegata enake ravni zdravilne učinkovine v telesu .
Leflunomide Teva treatment starts with a ‘loading dose' of 100 mg once a day for three days, followed by a maintenance dose. 
Zdravljenje z zdravilom Leflunomide Teva se začne z začetnim odmerkom 100 mg enkrat na dan prve tri dni, čemur sledi vzdrževalni odmerek.
This means that Leflunomide Teva is similar to a ‘reference medicine' already authorised in the European Union (EU) called Arava. 
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Arava.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Leflunomide Teva, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
What are the benefits and risks of Leflunomide Teva? 
Kakšne so koristi in tveganja, povezani z zdravilom Leflunomide Teva?
This is a summary of the European public assessment report (EPAR) for Leflunomide Teva. 
Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Leflunomide Teva.
Because Leflunomide Teva is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Ker je zdravilo Leflunomide Teva generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so koristi in tveganja enaki kot pri referenčnem zdravilu.
Leflunomide Teva EMA/CHMP/149365/2011 
EMA/149306/2011
Its effect may improve further for up to six months. 
Učinki zdravi8la se lahko nato v nadaljnjih šestih mesecih še izboljšujejo.
It reduces inflammation by reducing the production of immune cells called ‘lymphocytes', which are responsible for inflammation. 
Zmanjša vnetje tako, da zmanjša nastajanje imunskih celic, imenovanih „limfociti“, ki povzročajo vnetje.
Leflunomide Teva treatment should be started and supervised by a specialist who has experience in the treatment of rheumatoid arthritis. 
Zdravljenje z zdravilom Leflunomide Teva mora uvesti in nadzorovati zdravnik specialist, ki ima izkušnje z zdravljenjem revmatoidnega artritisa.
For more information about treatment with Leflunomide Teva, read the package leaflet (also part of the EPAR) or contact your 
Za več informacij o zdravljenju z zdravilom Leflunomide Teva preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Other information about Leflunomide Teva 
Druge informacije o zdravilu Leflunomide Teva
The CHMP concluded that, in accordance with EU requirements, Leflunomide Teva has been shown to have comparable quality and to be bioequivalent to Arava. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Leflunomide Teva primerljivo raven kakovosti kot zdravilo Arava ter da mu je biološko enakovredno.
Leflunomide Teva is used to treat adults with active rheumatoid arthritis (an immune system disease 
Zdravilo Leflunomide Teva se uporablja za zdravljenje odraslih z aktivnim revmatoidnim artritisom (boleznijo imunskega sistema, ki povzroča vnetje sklepov).
The European Commission granted a marketing authorisation valid throughout the European Union for Leflunomide Teva to TEVA Pharma B.V. on 10 March 2011. 
Evropska komisija je dovoljenje za promet z zdravilom Leflunomide Teva, veljavno po vsej Evropski uniji, odobrila družbi TEVA Pharma B.V.
Because Leflunomide Teva is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Arava. 
Ker je zdravilo Leflunomide Teva generično zdravilo, so bile študije pri bolnikih omejene ne preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Arava.
Why has Leflunomide Teva been approved? 
Zakaj je bilo zdravilo Leflunomide Teva odobreno?
Leflunomide Teva is a medicine that contains the active substance leflunomide. 
Leflunomide Teva je zdravilo, ki vsebuje zdravilno učinkovino leflunomid.
The active substance in Leflunomide Teva, leflunomide, is an immunosuppressant. 
Zdravilna učinkovina v zdravilu Leflunomide Teva, leflunomid, je sredstvo za zaviranje imunske odzivnosti.
The doctor should carry out blood tests to check the patient's liver, white blood cell counts and platelet counts before prescribing Leflunomide Teva, and regularly during treatment. 
Zdravnik mora, preden predpiše zdravilo Leflunomide Teva in nato v rednih presledkih med zdravljenjem, opraviti krvne preiskave, s katerimi preveri delovanje bolnikovih jeter ter število belih krvnih celic in krvnih ploščic.
Leflunomide Teva is a ‘generic medicine'. 
Zdravilo Leflunomide Teva je generično zdravilo.
How has Leflunomide Teva been studied? 
Kako je bilo zdravilo Leflunomide Teva raziskano?
How does Leflunomide Teva work? 
Kako zdravilo Leflunomide Teva deluje?
The Committee recommended that Leflunomide Teva 
Odbor je priporočil, da se za zdravilo Leflunomide Teva odobri dovoljenje za promet.
This is very important. 
To je zelo pomembno.
It is therefore important that you know about these medicines too. 
Zato je pomembno, da poznate tudi ta zdravila.
The study was prematurely stopped after 60 weeks. 
Raziskavo so po 60 tednih predčasno končali.
Such changes may in part be linked to disease control and life style. 
Take spremembe so deloma lahko povezane z obvladanjem bolezni in načinom življenja.
In some patients additional Factor VIII was given. 
Nekateri bolniki so dodatno prejemali faktor VIII.
Date of first opening: 
Datum prvega odprtja:
The following observations were made: 
Izsledki so bili naslednji:
These changes may be seen on an ECG (electrocardiogram). 
Spremembe so vidne na EKG (elektrokardiogramu).
Practical recommendations deriving from this study are displayed below. 
Praktična priporočila, ki izhajajo iz te študije, so opisana v nadaljevanju.
This medicine contains sorbitol. 
To zdravilo vsebuje sorbitol.
% White % Black % Asian 
% belci % črnci % azijska
In addition, most radioactivity (56%) was excreted between 24 and 96 hours after dosing. 
Poleg tega se je večina radioaktivnosti (56%) izločila med 24 in 96 urami po vnosu odmerka.
The significance of this finding is being further monitored. 
Pomen tega izsledka nadalje spremljajo.
A total of 10% of patients had previously used enfuvirtide. 
Skupno10% bolnikov je v preteklosti uporabljalo enfuvirtid.
In the majority of these patients the bleeding may have had other causes. 
Pri večini teh bolnikov so lahko prisotni drugi vzroki krvavitve.
Harmful for those suffering from alcoholism. 
Škodljivo za alkoholike.
This will be based on the child's body surface area in metres squared. 
Odvisen je od otrokove telesne površine v kvadratnih metrih.
Primary PI mutations 
Primarne mutacije PI
The mean half-life was 5.5 (females) or 6.0 hours (males). 
Povprečna razpolovna doba je med 5,5 (ženske) in 6,0 ure (moški).
Patients should be instructed accordingly. 
Bolnike je treba o tem ustrezno poučiti.
Aptivus is not a cure for HIV infection: 
Zdravilo Aptivus ni zdravilo za okužbo s HIV:
Date of first opening of the bottle: 
Datum prvega odprtja steklenice:
Effects of food on oral absorption 
Vpliv hrane na peroralno absorpcijo
For example they had other medical conditions or were receiving other medicine that may have caused the bleeding. 
Imeli so na primer druge bolezni ali so prejemali druga zdravila, ki bi lahko povzročila krvavitev.
ECG evaluation 
Ocena EKG
Autoimmune disorders may occur many months after the start of treatment. 
Avtoimunske motnje se lahko pojavijo več mesecev po začetku zdravljenja.
N n (%) 
n (%)
Store in a refrigerator (2°C to 8°C). 
Shranjujte v hladilniku (2°C do 8°C).
Overall population FAS 
Vsa populacija FAS
Tipranavir is extensively bound to plasma proteins (>99.9%). 
Tipranavir se obsežno veže na beljakovine v plazmi (> 99,9%).
You should therefore remain in regular contact with your doctor. 
Zato morate imeti redne stike z zdravnikom.
Tipranavir: ↔ Valaciclovir: ↔ 
tipranavir: ↔ valaciklovir: ↔
Once the bottle is opened your child should use the medicine within 60 days. 
Po prvem odprtju stekleničke mora vaš otrok zdravilo uporabiti v 60 dneh.
Treatment of overdose should consist of general supportive measures, including monitoring of vital signs and observation of the patient's clinical status. 
Zdravljenje mora zajemati splošne podporne ukrepe, med njimi spremljanje življenjskih znakov in bolnikovega kliničnega stanja.
When the enzyme is blocked, the virus does not reproduce normally, slowing down the infection. 
Če je encim blokiran, se virus ne more normalno razmnoževati, kar upočasni okužbo.
The dose for children, aged 2 to 12 years, will be calculated by the doctor. 
Odmerek za otroke od 2 do 12 let izračuna zdravnik.
In more than half of the reported cases, treatment with protease inhibitors was continued or reintroduced if treatment had been discontinued. 
Pri več kot polovici primerov, o katerih so poročali, so zdravljenje z zaviralci proteaze nadaljevali ali ga po prekinitvi ponovno uvedli.
Number of Patients Age-Median (years) Gender 
Vrednost število bolnikov starost-srednja (leta) spol
Data on the 29 patients who switched to capsules during the first 48 weeks are presented. 
Prikazani so podatki za 29 bolnikov, ki so prešli na kapsule v prvih 48 tednih.
One patient in the tipranavir arm had four mutations. 
En bolnik v skupini s tipranavirjem je imel štiri mutacije.
Patients should be advised of the need to take Aptivus and ritonavir every day as prescribed. 
Bolnike je treba poučiti, da morajo zdravili Aptivus in ritonavir jemati vsak dan, kot je predpisano.
Moreover, in case of withdrawal of glucocorticoids progressive dose reduction may have to be performed over a longer period. 
Poleg tega je treba v primeru ukinitve glukokortikosteroidov progresivno zmanjševati odmerek dlje časa.
Monitoring of hepatic tests should be done prior to initiation of therapy, after two, four and then every four weeks until 24 weeks, and then every eight to twelve weeks thereafter. 
Preiskave jetrnega delovanja je treba opraviti pred začetkom zdravljenja, po dveh in štirih tednih, nato vsake štiri tedne do konca 24. tedna, pozneje pa vsakih osem do dvanajst tednov.
The effects were reversible with termination of treatment. 
Učinki so bili reverzibilni in so ob koncu zdravljenja minili.
Tipranavir should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus. 
Tipranavir smemo uporabiti med nosečnostjo samo, če pričakovana korist opravičuje možno tveganje za plod.
For this reason it is very important that you tell your doctor about any changes in your health. 
Zato je zelo pomembno, da zdravnika obvestite o vseh spremembah svojega zdravja.
A pharmacokinetic interaction is mechanistically unexpected and the interaction has not been confirmed in a controlled interaction study. 
Farmakokinetične interakcije iz mehanskega vidika ni pričakovati in v nadzorovani raziskavi o interakcijah tudi ni bila potrjena interakcija.
This may be in the skin or joints. 
Pojavljajo se lahko v koži ali sklepih.
However, in some cases the role of tipranavir cannot be excluded. 
V nekaterih primerih pa vloge tipranavirja ne moremo izključiti.
The trial evaluated pharmacokinetics, safety and tolerability, as well as virologic and immunologic responses through 48 weeks. 
V raziskavi so ocenjevali farmakokinetiko, varnost in prenašanje, kot tudi virološki in imunološki odziv v obdobju 48 tednov.
Known and theoretical interactions with selected antiretrovirals and non-antiretroviral medicinal products are listed in the table below. 
Znane in teoretično možne interakcije z izbranimi protiretrovirusnimi in neprotiretrovirusnimi zdravili so navedene v spodnji preglednici.
Protein binding studies have shown that the antiviral activity of tipranavir decreases on average 3.75fold in conditions where human serum is present. 
Raziskave o vezavi na beljakovine so pokazale, da se protivirusno delovanje tipranavirja za povprečno 3,75-krat zmanjša v razmerah, v katerih je prisoten človeški serum.
Potential interactions with renal transporters cannot be fully excluded. 
Možnih interakcij z ledvičnimi prenašalci ni mogoče povsem izključiti.
Haemophiliac patients should therefore be made aware of the possibility of increased bleeding. 
Bolnike s hemofilijo je treba opozorili na možnost povečanega krvavenja.
Soft capsule. 
mehka kapsula
Interaction Geometric mean change (%) 
Interakcija Srednja geometrična sprememba (%)
Since currently only limited efficacy and safety data are available for adolescents (see section 5.1) close monitoring of virologic response and tolerance is particularly warranted in this patient group. 
Ker je trenutno s tem režimom odmerjanja na voljo malo podatkov o učinkovitosti in varnosti pri mladostnikih (glejte poglavje 5.1), je še posebej pomembno, da natančno spremljamo virološki odziv in toleranco pri tej skupini bolnikov.
Includes abdominal pain (N=1) and dyspepsia (N=1). 
Zajema abdominalno bolečino (n=1) in dispepsijo (n=1).
Number of TPV Score Mutations** 
Število mutacij TPV **
The increase of tipranavir Cmin may be clinically relevant. 
Povečanje tipranavirjeve Cmin je lahko klinično pomembno.
If Aptivus has been prescribed for your child, please note that all information in this leaflet is addressed to your child (in this case please read “your child” instead of “you”). 
Če je bilo zdravilo Aptivus predpisano vašemu otroku, se vse informacije v tem navodilu nanašajo na vašega otroka (v tem primeru prosimo berite "vaš otrok" namesto "vi").
Mutations at protease codons 33, 82, 84 and 90 
Mutacije na proteaznih kodonih 33, 82, 84 in 90
Phosphodiesterase 5 (PDE5) inhibitors Sildenafil 
Zaviralci fosfodiesteraze 5 (PDE5) Sildenafil
Agents that are contraindicated specifically due to the expected magnitude of interaction and potential for serious adverse reactions are detailed in this section, and listed in section 4.3. 
Zdravila, ki so kontraindicirana posebej zaradi obsega pričakovanih interakcij in možnih resnih neželenih učinkov, so podrobno opisana v tem poglavju in našteta v poglavju 4.3.
Baseline HIV-1 RNA (log10 copies/ml) 
Izhodiščna HIV-1 RNA (log10 kopij/ml)
You should therefore remain in regular contact with your child's doctor. 
Zato morate imeti redne stike z otrokovim zdravnikom.
The limited data available from a phase IIa study in HIV-infected patients suggest that no significant interaction is expected between nevirapine and TPV/r. 
Manjše število podatkov iz raziskave faze IIa pri s HIV okuženih bolnikih kaže, da med nevirapinom in TPV/r ni pričakovati pomembnih interakcij.
There are no adequate data from the use of tipranavir in pregnant women. 
Ni zadostnih podatkov o uporabi tipranavirja pri nosečnicah.
The available clinical data do not support the use of Aptivus oral solution in adolescents or adults. 
Dosegljivi klinični podatki ne podpirajo uporabe peroralne raztopine Aptivus pri mladostnikih ali odraslih.
Therefore, a modification of Aptivus exposure cannot be ruled out. 
Zato spremembe izpostavljenosti zdravilu Aptivus ni mogoče izključiti.
Despite an almost half reduction of C12, previous clinical studies with this combination did not evidence an impaired outcome. 
Kljub skoraj polovičnemu zmanjšanju C12 v kliničnih študijah za to kombinacijo ni bil dokazan škodljiv vpliv na izid zdravljenja.
Do not store below 15°C. 
Shranjujte pri temperaturi do 15°C.
Although data available at this stage are currently limited to allow a definitive analysis, they suggest that the pharmacokinetic profile is unchanged in older people and comparable between races. 
Čeprav je v zdajšnji fazi za dokončno analizo na voljo malo podatkov, le-ti kažejo, da se farmakokinetični profil pri starejših osebah ne spremeni in je primerljiv med različnimi rasami.
Tipranavir Cmin ↓ 61% (compared to historical data) 
Cmin tipranavirja ↓ 61% (v primerjavi s prejšnjimi podatki)
The combination is not recommended. 
Kombinacije ne priporočamo.
*Carbamazepine total = total of carbamazepine and epoxycarbamazepine (both are pharmacologically active moieties). 
*karbamazepin skupno = skupno karbamazepin in epoksikarbamazepin (oba sta farmakološko aktivna)
Aptivustreatment is therefore appropriate for your child. 
Zdravljenje z zdravilom Aptivus je zato primerno za vašega otroka.
Liver impairment could therefore result in an increase of tipranavir exposure and a worsening of its safety profile. 
Jetrna okvara bi zato lahko povečala izpostavljenost tipranavirju in poslabšala njegovo varnost.
PHARMACEUTICAL FORM AND CONTENTS 120 soft capsules 
FARMACEVTSKA OBLIKA IN VSEBINA 120 mehkih kapsul
Previous ADI* 
Prejšnji ADI*
Aptivustreatment is therefore appropriate for you. 
Zdravljenje z zdravilom Aptivusje zato primerno za vas.
In both studies, a total of 67% patient viruses were resistant and 22% were possibly resistant to the pre-selected comparator PIs. 
V obeh preskušanjih je bilo skupno 67% virusov odpornih in 22% verjetno odpornih proti vnaprej izbranemu primerjanemu zaviralcu proteaze.
Median (Min - Max) 
Srednji (min - maks)
It is not known whether Aptivus may be used safely during pregnancy. 
Ni znano, ali je uporaba zdravila Aptivus med nosečnostjo varna.
The majority of the effects in repeat-dose toxicity studies appeared at systemic exposure levels which are equivalent to or even below the human exposure levels at the recommended clinical dose. 
Večina učinkov v študijah toksičnosti po ponovljenih odmerkih se je pojavila pri ravneh, pri katerih je prišlo do sistemske izpostavljenosti, in ki so enake ali celo manjše od ravni izpostavljenosti, do katere prihaja pri dajanju priporočenih kliničnih odmerkov pri ljudeh.
A causal relationship has been evoked, although the mechanism of action had not been elucidated. 
Vzročna povezanost je bila navedena, vendar njenega mehanizma niso pojasnili.
For this reason it is very important that you tell your child's doctor about any changes in their health. 
Zato je zelo pomembno, da otrokovega zdravnika obvestite o vseh spremembah njegovega zdravja.
Pharmacotherapeutic group: antivirals for systemic use, protease inhibitors, ATC code: J05AE09 
Farmakoterapevtska skupina: zdravila za sistemsko zdravljenje virusnih infekcij, zaviralci proteaz, oznaka ATC: J05AE09
At present there are no results from controlled trials evaluating the effect of tipranavir on clinical progression of HIV. 
Zaenkrat ni izsledkov nadzorovanih preskušanj, ki bi vrednotila učinek tipranavirja na klinično napredovanje HIV.
No clinically significant interaction is observed. 
Ni klinično pomembne interakcije.
New ENF No New ENF* 
Prvič ENF Brez ENF*
In vitro, there is an inverse correlation between the degree of resistance to tipranavir and the capacity of viruses to replicate. 
In vitro obstaja inverzna korelacija med stopnjo odpornosti proti tipranavirju in replikacijsko kapaciteto virusa.
What Aptivus is and what it is used for 
Kaj je zdravilo Aptivus in za kaj ga uporabljamo
Your doctor, together with you, will decide which other medicines you should take. 
Zdravnik bo skupaj z vami določil, katera druga zdravila morate jemati.
No cases of Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis have been reported in the clinical development programme of tipranavir. 
O primerih Stevens-Johnsonovega sindroma ali toksične epidermalne nekrolize v programu kliničnega razvoja tipranavirja niso poročali.
Itraconazole or ketoconazole should be used with caution (doses 200 mg/day are not recommended). 
Itrakonazol ali ketokonazol moramo uporabljati previdno (odmerkov nad 200 mg na dan ne priporočamo).
Aptivus should be prescribed by physicians who are experienced in the treatment of HIV-1 infection. 
Zdravilo Aptivus smejo predpisati samo zdravniki, ki imajo izkušnje z zdravljenjem okužbe s HIV-1.
However, without new enfuvirtide some patients began to lose antiviral activity between weeks 4 and 8. 
Toda pri nekaterih bolnikih, ki niso prejeli enfuvirtida, se je protivirusna učinkovitost med 4. in 8. tednom začela manjšati.
Therefore, an alternative, effective, safe method of contraception should be used during treatment (see section 4.5). 
Med zdravljenjem je zato treba uporabljati drugo, učinkovito in varno kontracepcijsko metodo (glejte poglavje 4.5).
Median (Min - Max) % with VL > 100,000 copies/ml 
Srednja (min - maks) % z VL > 100.000 kopij/ml
Bleeding observed in rats was associated with prolonged prothrombin time (PT), activated partial thromboplastin time (APTT) and a decrease in some vitamin K dependent factors. 
Krvavitve, ki so jih zasledili pri podganah, so bile povezane s podaljšanim protrombinskim časom (PT), aktiviranim delnim tromboplastinskim časom (APTT) in z zmanjšanjem nekaterih od vitamina K odvisnih faktorjev.
RESIST study 
Raziskava RESIST
Only a few metabolites were found in plasma, and all were at trace levels (0.2% or less of the plasma radioactivity). 
V plazmi so odkrili samo nekaj presnovkov, od katerih so bile pri vseh prisotne samo sledi (0,2% ali manj radioaktivnosti v plazmi).
Conclusions regarding the relevance of particular mutations or mutational patterns are subject to change with additional data, and it is recommended to always consult current interpretation systems for analysing resistance test results. 
Sklepi o pomenu določenih mutacij ali mutacijskih vzorcev se lahko po pridobitvi dodatnih podatkov spremenijo, zato je treba pri analizah rezultatov testiranja odpornosti vedno upoštevati najnovejše sisteme njihove interpretacije.
Aptivus oral solution contains vitamin E. Your child should not take any additional vitamin E supplements. 
ZdraviloAptivus peroralna raztopina vsebuje vitamin E. Vaš otrok ne smete jemati nobenih dodatnih nadomestkov vitamina E
No information is available for the parameters AUC and Cmax. 
O AUC in Cmax ni podatkov.
Absorption of tipranavir in humans is limited, though no absolute quantification of absorption is available. 
Absorpcija tipranavirja je pri človeku omejena, vendar ni podatkov o njeni absolutni količinski določitvi.
Administration of activated charcoal may also be used to aid in removal of unabsorbed substance. 
Za odstranjevanje neabsorbirane učinkovine lahko dajemo tudi aktivno oglje.
The 1483 patients included in the primary analysis had a median age of 43 years (range 17-80), were 86% male, 75% white, 13% black and 1% Asian. 
Srednja starost 1483 bolnikov, vključenih v primarno vmesno analizo, je bila 43 let (17 do 80), 86% je bilo moških, 75% bele, 13% črne in 1% azijske rase.
This can lead to permanent disability or death, and has occurred in some patients treated with Aptivus in clinical trials. 
Lahko povzroči trajno invalidnost ali smrt, ki so jo zasledili v kliničnih raziskavah pri nekaterih bolnikih, zdravljenih z zdravilom Aptivus.
The effects of high fluticasone systemic exposure on ritonavir plasma levels are as yet unknown. 
Učinki velike sistemske izpostavljenosti flutikazonu na raven ritonavirja v plazmi še niso znani.
- with ENF (FAS) - without ENF (FAS) 
PP - z ENF (FAS) - brez ENF (FAS)
Number of patients Primary efficacy endpoint: % with VL < 400 
Primarni opazovani dogodek za oceno učinkovitosti:% z VL < 400
Therefore, it is important that your child continues taking Aptivus correctly, as described above. 
Zato je pomembno, da vaš otrok nadaljuje z jemanjem zdravila Aptivus pravilno, kot je opisano v teh navodilih.
If affected, your child should not drive or operate machinery. 
Če se pojavita, vaš otrok ne sme voziti ali upravljati strojev.